SCHEMBL4409801

SCHEMBL4409801

CCCCC(O)CO.CCCCCCCCOCCO

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.66
MEN1 O00255 2/20 0.66
KMT2A Q03164 2/20 0.66
THRB P10828 1/20 0.66
MAPT P10636 1/20 0.66
USP2 O75604 1/20 0.62
TSHR P16473 1/20 0.55
PLA2G2C Q5R387 2/20 0.51
LPAR5 Q9H1C0 1/20 0.41
PSMD14 O00487 2/20 0.40
PLA2G1B P04054 2/20 0.40
MMP2 P08253 2/20 0.40
ATG4B Q9Y4P1 2/20 0.40
LMNA P02545 2/20 0.40
HSP90AA1 P07900 1/20 0.40
SPHK1 Q9NYA1 1/20 0.40
KDM4E B2RXH2 1/20 0.40
DUSP3 P51452 1/20 0.40
RAD52 P43351 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Di(Hydroxyethyl)Ether SCHEMBL28181733 0.93 HTT (0.59) HTTMEN1KMT2ATHRBMAPT
Triethylene Glycol SCHEMBL28094364 0.91 TSHR (0.63) HTTMEN1KMT2ATHRBMAPT
SCHEMBL27968085 0.91 TSHR (0.63) HTTMEN1KMT2ATHRBMAPT
SCHEMBL28165908 0.91 USP2 (0.69) HTTMEN1KMT2ATHRBMAPT
SCHEMBL28189988 0.91 USP2 (0.69) HTTMEN1KMT2ATHRBMAPT
SCHEMBL16218012 0.91 USP2 (0.69) HTTMEN1KMT2ATHRBMAPT
SCHEMBL27280251 0.91 USP2 (0.69) HTTMEN1KMT2ATHRBMAPT
Glycerin SCHEMBL17668302 0.89 MEN1 (0.77) HTTMEN1KMT2ATHRBMAPT
SCHEMBL10406329 0.87 USP2 (0.69) HTTMEN1KMT2ATHRBMAPT
SCHEMBL8585380 0.87 USP2 (0.69) HTTMEN1KMT2ATHRBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220031640-A1 FORMULATIONS FOR EPIDURAL REPAIR CLARIDEI LABORATORIES, INC. 2022-02-03 US disclosed
US-11135184-B2 Formulations for epidermal repair CLARIDEI LABORATORIES, INC. (US) 2021-10-05 US disclosed
US-20180289642-A1 FORMULATIONS FOR EPIDERMAL REPAIR CLARIDEI LABORATORIES, INC. 2018-10-11 US disclosed
US-20170020805-A1 CORDYCEPS CONTAINING TOPICAL SKIN CARE FORMULATION NSE PRODUCTS, INC. (US) 2017-01-26 US disclosed
WO-2016197144-A1 CORDYCEPS CONTAINING TOPICAL SKIN CARE FORMULATION NSE PRODUCTS, INC. (US) 2016-12-08 WO disclosed
US-20160184245-A1 FORMULATIONS FOR EPIDERMAL REPAIR CLARIDEI LABORATORIES, INC. 2016-06-30 US disclosed
EP-2494973-A1 Topical compositions for the treatment and prevention of skin diseases, in particular radiation dermatitis caused by ionising radiation Sinerga Group S.r.l. (IT) 2012-09-05 EP disclosed
US-20090317345-A1 Antiperspirant/Deodorant Gel Composition With Low Pouring Temperature REVLON CONSUMER PRODUCTS CORPORATION (US) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180289642-A1 FORMULATIONS FOR EPIDERMAL REPAIR KRT18, CUTA, DSG1 HTT 4239/4885MEN1 4525/4885KMT2A 4573/4885
US-20160184245-A1 FORMULATIONS FOR EPIDERMAL REPAIR KRT18, CUTA, DSG1 HTT 4195/4885MEN1 4505/4885KMT2A 4502/4885
US-20090317345-A1 Antiperspirant/Deodorant Gel Composition With Low Pouring Temperature DRD4, AASDHPPT, DRD5 HTT 804/4885MEN1 4342/4885KMT2A 1771/4885
US-20220031640-A1 FORMULATIONS FOR EPIDURAL REPAIR CUTA, EPHB1, EPHB2 HTT 3855/4885MEN1 3465/4885KMT2A 3869/4885
US-11135184-B2 Formulations for epidermal repair KRT18, CUTA, DSG1 HTT 4195/4885MEN1 4505/4885KMT2A 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.